JPS6247190B2 - - Google Patents
Info
- Publication number
- JPS6247190B2 JPS6247190B2 JP114781A JP114781A JPS6247190B2 JP S6247190 B2 JPS6247190 B2 JP S6247190B2 JP 114781 A JP114781 A JP 114781A JP 114781 A JP114781 A JP 114781A JP S6247190 B2 JPS6247190 B2 JP S6247190B2
- Authority
- JP
- Japan
- Prior art keywords
- camptothecin
- group
- lower alkyl
- dxd
- acetylcamptothecin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 44
- 229940127093 camptothecin Drugs 0.000 claims description 28
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 26
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000002130 sulfonic acid ester group Chemical group 0.000 claims 1
- 238000003756 stirring Methods 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000007858 starting material Substances 0.000 description 7
- ASVIEXKOXDCZDF-QFIPXVFZSA-N 1v364427ug Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(OC(C)=O)CC)C4=NC2=C1 ASVIEXKOXDCZDF-QFIPXVFZSA-N 0.000 description 6
- ASVIEXKOXDCZDF-UHFFFAOYSA-N O-acetylcamptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(OC(C)=O)CC)C4=NC2=C1 ASVIEXKOXDCZDF-UHFFFAOYSA-N 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000001816 cooling Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- -1 camptothecin compound Chemical class 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 241000759909 Camptotheca Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP114781A JPS57116074A (en) | 1981-01-09 | 1981-01-09 | Novel camptothecin derivative and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP114781A JPS57116074A (en) | 1981-01-09 | 1981-01-09 | Novel camptothecin derivative and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57116074A JPS57116074A (en) | 1982-07-19 |
| JPS6247190B2 true JPS6247190B2 (zh) | 1987-10-06 |
Family
ID=11493323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP114781A Granted JPS57116074A (en) | 1981-01-09 | 1981-01-09 | Novel camptothecin derivative and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57116074A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63164287U (zh) * | 1987-04-16 | 1988-10-26 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
| US5446047A (en) * | 1992-07-23 | 1995-08-29 | Sloan-Kettering Institute For Cancer Research | Camptothecin analogues |
| US5391745A (en) * | 1992-07-23 | 1995-02-21 | Sloan-Kettering Institute For Cancer Research | Methods of preparation of camptothecin analogs |
| US6214836B1 (en) * | 1995-06-06 | 2001-04-10 | Dr. Reddy's Research Foundation | Water soluble analogues of 20(S)-camptothecin |
| SG104284A1 (en) | 1996-10-30 | 2004-06-21 | Tanabe Seiyaku Co | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof |
| CZ298259B6 (cs) | 2000-02-28 | 2007-08-08 | Aventis Pharma S. A. | Farmaceutická kombinace k lécení rakoviny obsahující CPT-11 a capecitabin |
| US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| US6486320B2 (en) | 2000-09-15 | 2002-11-26 | Aventis Pharma S.A. | Preparation of camptothecin and of its derivatives |
| AU2002216029B2 (en) | 2000-10-27 | 2006-01-05 | Pfizer, Inc. | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |
-
1981
- 1981-01-09 JP JP114781A patent/JPS57116074A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63164287U (zh) * | 1987-04-16 | 1988-10-26 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57116074A (en) | 1982-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6247190B2 (zh) | ||
| JPH0639468B2 (ja) | ヒドロキノン誘導体 | |
| JPS6247873B2 (zh) | ||
| JP5960130B2 (ja) | テセタキセルおよび関連化合物ならびに対応する合成中間体の調製 | |
| WO1996026181A1 (fr) | Derives d'aminotetralone et leurs procede de production | |
| JPH0129792B2 (zh) | ||
| JP5587350B2 (ja) | ラメルテオンの調製方法 | |
| JPS6011704B2 (ja) | ５−フルオルウラシル誘導体の製造法 | |
| JPH0429674B2 (zh) | ||
| JP2004506628A (ja) | ビタミンｅの調製に用いるための中間体 | |
| CN117886759A (zh) | 一种α-三氟甲基烯烃C(sp3)-F直接功能化的方法 | |
| JP2662162B2 (ja) | ３−アルキルピロールの製造法 | |
| JPS63250396A (ja) | ３′−アジド−３′−デオキシチミジン誘導体 | |
| KR100488393B1 (ko) | 2-아자비사이클로[2.2.1]헵탄유도체,이의제조방법및사용방법 | |
| JP2662607B2 (ja) | ビシクロ［８．３．０］トリデカ―９，１３―ジエン―２，７―ジイン誘導体 | |
| JPH0449269A (ja) | 光学活性なペンタン誘導体 | |
| JPH08325238A (ja) | ５−トリフルオロメチルウラシル誘導体およびその製造方法 | |
| JPH01319496A (ja) | ウラシル誘導体 | |
| Sakagami et al. | Scalable synthesis of (+)-2-amino-3-fluorobicyclo [3.1. 0] hexane-2, 6-dicarboxylic acid as a potent and selective group II metabotropic glutamate receptor agonist | |
| JPH0465066B2 (zh) | ||
| KR20240024937A (ko) | Cyp11a1 억제제 및 그의 중간체의 제조 방법 | |
| CN118027091A (zh) | 一种曲前列环素及其中间体的制备方法 | |
| JP2782755B2 (ja) | ３ａ，８ｂ―シス―ジヒドロ―３Ｈ―５，７―ジブロモシクロペンタ［ｂ］ベンゾフランの製造法 | |
| JP2651658B2 (ja) | １，２，３，５−テトラヒドロインドリジン誘導体 | |
| JPH0234346B2 (zh) |